Abstract
"Given the health care industry' s reliance on diagnostics to properly treat
patients, deals between diagnostics companies bode well for all facets of
industry. While larger companies are likely to continue to consolidate,
smaller companies and academic institutions will stay active in deals by
licensing biomarkers and technologies." - Catherine Cuddihee, M.S.,
Principal Director
Introduction
IVD (in vitro diagnostics) tests are essential to the practice of health care
worldwide: an estimated 60-70% of medical decisions involve a diagnostic test.
This report focuses on IVD industry deals of the last few years and what they
reveal about the current strategies of some of the industry' s larger and
smaller companies.
Get the Answers You Need to Shape Your Strategy
Currently, IVD company revenues pale in comparison to those of the larger
biopharmaceutical companies, but there are signs of steady growth in this
highly segmented market. What is the value of today' s global IVD market?
How fast is it growing? Which segments are currently most profi table? Which
are showing strong growth? Which IVD suppliers accounted for nearly 80% of
worldwide sales in 2005?
Several large IVD M&As have occurred in recent years, but licensing deals have
been the most common type. How do licensing deals benefi t IVD suppliers?
What do big pharmaceutical and diagnostics companies gain? Which companies
have been most active in M&A and licensing deals? What does this activity
indicate about the future of the IVD industry?
The overall oncology therapeutic area has accounted for the majority of IVD
deals to date. Which oncology segments are most active? What other
therapeutic areas are generating notable deals? What types of diagnostic
assays and tests are most in demand? Which are being offered as "companion
diagnostics" to therapeutic agents? What new, DNA-based tests are in
development?
Scope
- The IVD marketplace: Current size, growth, segmentation, disease
areas, major and smaller IVD suppliers, 2005 sales.
- IVD mergers and acquisitions: 2005-2006, companies, segments,
values, signifi cance.
- IVD deals by disease areas: Oncology, cardiovascular, infectious
diseases, other therapeutic areas.
- IVD deal strategies: Different strategies drive deals in different
tiers of the IVD industry.
- Future IVD deals: Potential mergers and acquisitions as diagnostics
change and the IVD market continues to grow.
Mentioned in This Spectrum Report-Companies
- Abbott
- Affymetrix
- Agendia
- American Diagnostica
- Applied Imaging
- Arcturus
- AstraZeneca
- Athena Diagnostics
- Bayer Diagnostics
- Becton Dickinson
- Beckman Coulter
- BioMerieux
- Biosite
- CanAg Diagnostics
- Ciphergen
- Clarient
- Clinical Data
- Competitive Technologies
- Cytyc
- Dade Behring
- Diagnostic Products
- Corporation
- Diagnostic Systems
- Laboratories
- Epigenomics
- Exact Science
- Fisher Scientifi c
- Fujirebio Diagnostics
- GE Healthcare
- GeneOhm Sciences
- Gen-Probe
- Genzyme
- Health Discovery
- Corporation
- Inverness Medical
- Innovations
- Johnson & Johnson
- LabCorp
- LifeScan
- Lumigen
- Merck
- Monogram Biosciences
- Oncogene Sciences
- Oncomethylome Sciences
- Orion Genomics
- Ortho-Clinical
- Diagnostics
- Pathwork Informatics
- Power3 Medical
- Primagen
- Quest Diagnostics
- Ranbaxy Laboratories
- Response Biomedical
- Roche
- Rubicon Genomics
- Siemens
- Thermo Electron
- TriPath
- Veridex
| 
View Cart
